Targeting the Helicobacter pylori–Gastric Cancer Axis with Nanomaterials: From Infection Control to Tumor-Directed Therapy
Molecules · 01.11.2026 · 31 (21) · 3924
DOI: 10.3390/molecules31213924 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecules, online erschienen am 01.11.2026. Verfasst von Patrycja Jaroniek und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology and Infectious Biology, Institute of Microbiology, Biotechnology and Immunology, Faculty of Biology and Environmental Protec…. Hauptthemen laut MEDLINE: Helicobacter pylori, Helicobacter Infections, Stomach Neoplasms, Nanostructures. Die Arbeit nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Nosokomiale Infektionen
Abstract (Originalsprache)
Helicobacter pylori (H. pylori) infection promotes persistent mucosal inflammation, oxidative stress, epithelial injury, immune dysregulation, and progressive remodeling of the gastric microenvironment, thereby increasing the risk of gastric cancer (GC). Although H. pylori eradication and GC therapy are usually treated as separate clinical problems, they are linked by a continuum of pathogenic processes. Nanomaterial-based therapeutic systems may help overcome different barriers on this axis by improving drug stability and delivery, facilitating transport through mucus and biofilms, and enabling host-directed immunomodulation. This review focuses on polymeric, lipid-based, inorganic, hybrid, and stimuli-responsive approaches relevant to the management of H. pylori infection and the treatment of GC, emphasizing how carrier design can be adapted to different disease stages. Selected chitosan-based particles and functionalized poly(lactic acid) systems are discussed as examples of stage-adapted delivery strategies across the infection–cancer continuum. This review also describes three-dimensional and infection-associated GC models as tools for assessing nanoparticle penetration and therapeutic responses under more physiologically relevant conditions. Stage-adapted interventions are considered as distinct or potentially sequential approaches, rather than as a single validated platform combining bacterial eradication, inflammation control, mucosal repair, and anticancer therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Immunology and Infectious Biology, Institute of Microbiology, Biotechnology and Immunology, Faculty of Biology and Environmental Protection, University of Lodz, 91-278 Lodz, Poland.
- BioMedChem Doctoral School of the University of Lodz and Lodz Institutes of the Polish Academy of Sciences, University of Lodz, 91-278 Lodz, Poland.
ORCID-Profile: Weronika Gonciarz
Zitieren
APA
Jaroniek, P., Połomska, M., Chmiela, M., & Gonciarz, W. (2026). Targeting the Helicobacter pylori–Gastric Cancer Axis with Nanomaterials: From Infection Control to Tumor-Directed Therapy. Molecules, 31(21), 3924. https://doi.org/10.3390/molecules31213924
Vancouver
Jaroniek P, Połomska M, Chmiela M, Gonciarz W. Targeting the Helicobacter pylori–Gastric Cancer Axis with Nanomaterials: From Infection Control to Tumor-Directed Therapy. Molecules. 2026;31(21):3924. doi:10.3390/molecules31213924
BibTeX
@article{Jaroniek2026,
author = {Jaroniek, Patrycja and Połomska, Maria and Chmiela, Magdalena and Gonciarz, Weronika},
title = {Targeting the Helicobacter pylori–Gastric Cancer Axis with Nanomaterials: From Infection Control to Tumor-Directed Therapy},
journal = {Molecules},
year = {2026},
volume = {31},
number = {21},
pages = {3924},
doi = {10.3390/molecules31213924}
}
EUVIMED